90389-84-7

Basic information

• Product Name: (3-FLUOROBENZYL)METHYLAMINE
• Synonyms: (3-FLUOROBENZYL)METHYLAMINE;3-FLUORO-N-METHYLBENZYLAMINE;(3-Fluorobenzyl)methylamine95%;1-(3-fluorophenyl)-N-methyl-methanamine;(3-fluorophenyl)-N-methylmethanamine;90389-40-5 (Hydrochloride);Aids011076;Aids-011076
• CAS NO: 90389-84-7
• Molecular Formula: C₈H₁₀FN
• Molecular Weight: 139.17
• Product Categories: Amines and Anilines;Polyamines;API intermediates;Amines;C8;Nitrogen Compounds
• Mol File: 90389-84-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 183-184 °C(lit.)
• Flash Point: 152 °F
• Appearance: Colorless to tan/Liquid
• Density: 1.015 g/mL at 25 °C(lit.)
• Vapor Pressure: 1.6mmHg at 25°C
• Refractive Index: n20/D 1.4990(lit.)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.39±0.10(Predicted)
• CAS DataBase Reference: (3-FLUOROBENZYL)METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (3-FLUOROBENZYL)METHYLAMINE(90389-84-7)
• EPA Substance Registry System: (3-FLUOROBENZYL)METHYLAMINE(90389-84-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-36/39
• RIDADR: UN 2735 8/PG III
• WGK Germany: 2
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 90389-84-7(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

InChI:InChI=1/C8H10FN/c1-10-6-7-3-2-4-8(9)5-7/h2-5,10H,6H2,1H3/p+1

Upstream product

• 593-51-1 methylamine hydrochloride 
• 456-48-4 3-Fluorobenzaldehyde 
• 74-89-5 methylamine 
• 456-42-8 m-fluorobenzyl chloride 

Downstream Products

• 1174903-50-4 3-[[(3-fluorobenzyl)-methyl-amino]methyl]-5-(pyridin-4-yl)-1,3,4-oxadiazol-2(3H)-one 

Relevant articles and documents

Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors

‘precision medicine’ is characterized by the selection of targeted drugs based on genetic characteristics of tumor from patients, and no longer selected basis on the type of cancer tissue. Among them, clinical trials on neurotrophin receptor tyrosine kinase genes (NTRK) have proven that great anti-cancer effects can be achieved in different cancer patients. In this paper, a novel total of twenty compounds in two categories have been designed and synthesized. Results of Kinase activity tests showed that I-9 (TRKA IC50 = 1.3 nM, TRKAG595R IC50 = 6.1 nM), and I-10 (TRKA IC50 = 1.1 nM, TRKAG595R IC50 = 5.3 nM) have significant inhibitory activity, and results of cell viability tests showed that I-9 and I-10 can maintain a great inhibitory effect in the Ba/F3-LMNA-NTRK1 cell line(IC50 = 81.1 nM and 41.7 nM, respectively), and in Ba/F3-LMNA-NTRK1-G595R cell line, I-9 and I-10 have better cell activity (IC50 was 495.3 nM, 336.6 nM, respectively) compared with the positive control drug LOXO-101. These results indicate that I-9 and I-10 are potential TRK inhibitors that can overcome drug resistance for further investigation.

4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors

Novel 4-phenyl tetrahydroisoquinolines that inhibit both dopamine and norepinephrine transporters were designed and prepared. In this Letter, we describe the synthesis, in vitro activity and associated structure-activity relationships of this series. We also report the ex vivo NET occupancy of a representative compound, 41.

4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin

The present invention relates to a method of treating disorders by administering a compound of the formulae IA-IF. These compounds are tetrahydroisoquinolines of the following structure: wherein R1-R8 for compounds of each of the formulae IA, IB, IC, ID, IE and IF are as described herein.